Clinical Trial Update: Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

View source ↗

Summary

This update reports long-term follow-up data from the GEN-003-002 study evaluating efficacy and immunogenicity for genital herpes caused by HSV-2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes Simplex Virus Type 2 Infection

Drugs mentioned

• GEN-003

Snippet

Sponsor: Genocea Biosciences, Inc. | Conditions: Genital Herpes Simplex Type 2 | Status: COMPLETED